Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + anti-thymocyte globulin
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Cyclophosphamide and anti-thymocyte globulin (ATG) is a combination immunosuppressive regimen primarily used in allogeneic hematopoietic stem cell transplantation (HSCT). This combination works synergistically to prevent graft-versus-host disease (GVHD) and graft rejection. Cyclophosphamide, when administered post-transplant (PT-Cy), targets alloreactive T cells while sparing regulatory T cells. ATG binds to multiple T-cell specific antigens, leading to T-lymphocyte cell death via complement-mediated cytotoxicity or apoptosis. The combination has shown effectiveness in various transplant settings, including haploidentical, unrelated donor, and matched sibling donor transplants.
- Brand names
- CytoxanThymoglobulinAtgamNeosar
- Other names
- CY/ATGATG/PTCy
02
Targets
CD18 (Beta-2 integrin)Human leukocyte antigen class I/II moleculeCD2 (T-cell Surface Antigen CD2)CD1A (T-cell surface glycoprotein CD1a)CD3 (T-cell surface glycoprotein CD3)CD8A (CD8 alpha/beta Coreceptor)CD86 (T-lymphocyte activation antigen CD86)CD28 (Cluster of Differentiation 28)DNAIL2RA (Interleukin-2 receptor alpha subunit)CD4 (T lymphocyte surface antigen)PTPRC (Receptor-type tyrosine-protein phosphatase C)
Beyond the preview
Go deeper on cyclophosphamide + anti-thymocyte globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + anti-thymocyte globulin.